NCT01131403

Brief Summary

Study design: The purpose of the present study is to analyse of the influence of the application of the skin care products on the diaper area (Factor A) and the application of a cotton wool cloth, moistened with clear water on the diaper area (Faktor B) on the skin barrier function of the newborns during the first four weeks. Additionally, the microbiological colonisation of the skin will be observed. After four weeks all infants in both groups will obtain wet wipe and after 8 weeks a facultative measurement will be performed. Primary and secondary end points: In the present study, as a primary end point TEWL on the buttock was chosen, because the significant difference between the infants who were bathed and washed in the previous study was found. Secondary end points are the TEWL on the other measuring points, pH-value and SCH. Additionally, secondary end points are the D-Squame method and the cytokine measurement with Sebutapes. Hypotheses: The intention of the study is to evaluate, whether the using of wet wipe on the diaper area has an influence on the TEWL of the newborns. The following hypotheses are present below: H0 (Null hypothesis): The TEWL is indistinguishable between infants who get cleaned with wet wipe on the diaper area and infants who get cleaned with a cotton wool cloth, moistened with clear water on the diaper area, i.e. TEWL clear water is equal TEWL wet wipe against H1 (Alternative hypothesis - bilateral): The TEWL is distinguishable between infants who get cleaned with wet wipe on the diaper area and infants who get cleaned with a cotton wool cloth, moistened with clear water on the diaper area, i.e. TEWL clear water is not equal TEWL wet wipe

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2007

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2007

Completed
2.7 years until next milestone

First Submitted

Initial submission to the registry

May 26, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 27, 2010

Completed
Last Updated

February 13, 2025

Status Verified

May 1, 2007

Enrollment Period

5 months

First QC Date

May 26, 2010

Last Update Submit

February 11, 2025

Conditions

Keywords

IL-1α, skin care; baby wet wipes; full-term newborn; skin barrier function

Outcome Measures

Primary Outcomes (1)

  • TEWL

    TEWL= transepidermal waterloss

    second day of life, 14 day of life and 28 day of life

Secondary Outcomes (5)

  • pH

    second day of life, 14 day of life and 28 day of life

  • SCH

    2nd, 14th and 28th day of life

  • D-Squame

    2nd, 14th and 28th day of life

  • Interleukin-1α

    2nd, 14th and 28th day of life

  • microbiological colonisation

    2nd, 14th and 28th day of life

Study Arms (2)

BW= using baby wipes and CW= using cotton wool

wet wipe, cotton wool

Group 1 (BW),(n= 01-19):Using of wet wipe during the diaper changes Group 2 (CW),(n=20-40):Using a cotton wool cloth, moistened with clear water during the diaper changes.

Eligibility Criteria

Age0 Hours - 48 Hours
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)
Sampling MethodProbability Sample
Study Population

group of 40 healthy full-term newborn babies

You may qualify if:

  • Male and female term newborns from 37 completed weeks of gestation, age ≤ 48 hours
  • Written informed parental consent

You may not qualify if:

  • Any critically ill term newborn, i.e. septic infants, infants born with serious congenital malformation/defects, asphyxia, hydronephrosis, severe intracranial hemorrhage
  • Newborns with known immunodeficiency
  • Newborns with pre-existing skin disease with eruptions covering more than 50% of body surface i.e. congenital ichthyosis, congenital candidiasis
  • Newborn has relevant skin maceration, which influence the measurements or is communicable i.e. urticaria or herpes
  • Any acutely or chronically ill newborn with temperatures below 35°C or above 40°C

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Officials

  • Ulrike Blume-Peytavi, MD, PhD

    Department of Dermatology, Charite-Universitätsmedizin, Berlin

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Dr. med.

Study Record Dates

First Submitted

May 26, 2010

First Posted

May 27, 2010

Study Start

May 1, 2007

Primary Completion

October 1, 2007

Study Completion

October 1, 2007

Last Updated

February 13, 2025

Record last verified: 2007-05